Sign in
  • S&P 500 7,659.44 −1.09%
  • Dow Jones 52,002.41 −0.34%
  • Nasdaq 26,713.03 +0.08%
  • VIX 19.99 +21.45%
  • 10-year Treasury 5.09% −0.01
  • Dollar index 121.40 −0.14%
  • WTI crude $101.91 +1.04%

Biotech calendar: November 2027

Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in November 2027, from ClinicalTrials.gov.

Trial readouts

79 trials: 31 phase 3 (including phase 2/3) and 48 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.

Primary completionSponsorDrugConditionPhaseStatusRecord
Nov 20274D Molecular Therapeutics, Inc.4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationNeovascular Age-Related Macular Degeneration (nAMD)Phase 3RecruitingNCT07064759
Nov 2027AbbVieUbrogepantStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineMigrainePhase 3Active not recruitingNCT06417775
Nov 2027Bausch HealthLarsucosterolStudy to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)HepatitisPhase 3RecruitingNCT07428538
Nov 2027Beijing Keymed Biosciences Co., Ltd.CM512A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3)Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)Phase 3Not yet recruitingNCT07807826
Nov 2027Corvus Pharmaceuticals, Inc.Soquelitinib, Belinostat, PralatrexateSoquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Hel…Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma and 5 morePhase 3RecruitingNCT06561048
Nov 2027Daewoong Pharmaceutical Co. LTD.DWP16001, DWC202518To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC20251…T2DM (Type 2 Diabetes Mellitus)Phase 3Not yet recruitingNCT07619833
Nov 2027Elgan Pharma Ltd.ELGN-2112Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm InfantsIntestinal MalabsorptionPhase 3RecruitingNCT05670951
Nov 2027Eli Lilly and CompanyLY3537982, Pembrolizumab, Cisplatin and 2 moreA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-s…Carcinoma, Non-Small-Cell Lung, Neoplasm MetastasisPhase 3RecruitingNCT06119581
Nov 2027Eli Lilly and CompanyDonanemabA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)Alzheimer DiseasePhase 3Active not recruitingNCT05026866
Nov 2027Jiangsu Hengrui MedicineSHR-1819 InjectionA Study of SHR-1819 Injection in Adolescents With Severe Atopic DermatitisAdolescents With Moderate-to-severe Atopic DermatitisPhase 3RecruitingNCT07309055
Nov 2027Hanmi PharmaceuticalHM11260CA Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dap…Type 2 DiabetesPhase 3RecruitingNCT07379333
Nov 2027Huons Co., Ltd.HUC3-637, HUC3-637-REfficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular HypertensionPrimary Open Angle Glaucoma (POAG), Ocular HypertensionPhase 3RecruitingNCT07335211
Nov 2027Idorsia Pharmaceuticals Ltd.DaridorexantA Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the…Insomia DisorderPhase 3Not yet recruitingNCT07843329
Nov 2027Kissei PharmaceuticalKLH-2109, Leuprorelin acetateA Clinical Study of KLH-2109 in Patients With EndometriosisEndometriosisPhase 3Active not recruitingNCT07015268
Nov 2027Laboratoires TheasepofarsenStudy to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)Leber Congenital Amaurosis 10, Blindness and 8 morePhase 3RecruitingNCT06891443
Nov 2027Loxo Oncology, Inc.Pirtobrutinib, Ibrutinib, Acalabrutinib and 1 moreStudy of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Lymphoma, Mantle-CellPhase 3Active not recruitingNCT04662255
Nov 2027Neurocrine BiosciencesNBI-1117568NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaSchizophreniaPhase 3RecruitingNCT07105098
Nov 2027Neuvosyn Laboratories, LLCDesiccated Porcine Thyroid Extract TabletsAn Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of North Star Desiccated Porcine Thyroid Extract Tablets.HypothyroidismPhase 3RecruitingNCT07747103
Nov 2027NewAmsterdam Pharma Co N.V.obicetrapib 10 mg + ezetimibe 10 mg FDC dailyA CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary PlaqueLipidemia, Coronary Artery Disease and 1 morePhase 3Active not recruitingNCT06305559
Nov 2027Sinocelltech Ltd.SCTB35 injection, Rituxumab, Gemcitabine and 1 moreA Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractor…DLBCL - Diffuse Large B Cell LymphomaPhase 3RecruitingNCT07570823
Nov 2027UNITED THERAPEUTICS CorpInhaled Treprostinil, Treprostinil Ultrasonic NebulizerStudy of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)Progressive Pulmonary Fibrosis, Interstitial Lung DiseasePhase 3RecruitingNCT05943535
Nov 2027Vanda Pharmaceuticals Inc.iloperidoneRandomized Withdrawal Study in Patients With SchizophreniaSchizophreniaPhase 3RecruitingNCT06961968
Nov 2027Vanda Pharmaceuticals Inc.Tasimelteon Oral SuspensionEvaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric InsomniaInsomnia DisorderPhase 3RecruitingNCT06953869
Nov 1, 2027AstraZenecaDatopotamab deruxtecan, Durvalumab, Carboplatin and 4 morePhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Gen…NSCLCPhase 3Active not recruitingNCT05687266
Nov 1, 2027AstraZenecaCapivasertib, Fulvestrant, Palbociclib and 2 moreCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Locally Advanced (Inoperable) or Metastatic Breast CancerPhase 3Active not recruitingNCT04862663
Nov 1, 2027Otsuka PharmaceuticalJNT-517A Long-Term Study of JNT-517 in Participants With PhenylketonuriaPhenylketonuria (PKU)Phase 3RecruitingNCT06628128
Nov 1, 2027Taiho Oncology, Inc.Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine and 1 moreA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND St…Myelodysplastic Syndromes, Acute Myeloid Leukemia and 2 morePhase 2/3RecruitingNCT04256317
Nov 1, 2027YS Life Science Co., Ltd.Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®)A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular HypertensionPrimary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)Phase 3RecruitingNCT07661329
Nov 4, 2027AstraZenecaTozorakimabEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenViral Lung Infection and Acute Respiratory FailurePhase 3RecruitingNCT05624450
Nov 5, 2027GSKRisvutatug rezetecan (Ris-Rez), TopotecanA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]Neoplasms, LungPhase 3RecruitingNCT07099898
Nov 5, 2027SanofirilzabrutinibStudy to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line TreatmentImmune ThrombocytopeniaPhase 3RecruitingNCT07007962
Nov 2027AbbVieTelisotuzumab Adizutecan, Budigalimab, Pembrolizumab and 3 moreStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhi…Non Small Cell Lung Carcinoma, c-METPhase 1/2RecruitingNCT06772623
Nov 2027AbbVieIcalcaprantA Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II DisorderBipolar I Disorder, Bipolar II DisorderPhase 2RecruitingNCT06696755
Nov 2027AkesoAK139A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic DermatitisModerate-to-Severe Atopic DermatitisPhase 2Not yet recruitingNCT07502222
Nov 2027AkesoAK129, AK117A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaClassic Hodgkin LymphomaPhase 1/2RecruitingNCT06642792
Nov 2027Alto Neuroscience, Inc.ALTO-207ALTO-207 in Adults With Treatment-resistant Depression (TRD)Treatment-resistant Depression (TRD)Phase 2RecruitingNCT07553637
Nov 2027Angitia Incorporated LimitedAGA2115Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)Osteogenesis Imperfecta (OI)Phase 2RecruitingNCT07062588
Nov 2027BIONCaRT GmbHBP CC 001Safety and Efficacy of hUC-MSC for the Treatment of Cartilage Damage in the Knee JointCartilage DamagePhase 1/2RecruitingNCT06981741
Nov 2027Beijing Sungen Biomedical Technology Co., LtdSGC001 injectionStudy of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary EfficacyAcute PancreatitisPhase 2RecruitingNCT07803965
Nov 2027BioAge Labs, Inc.Oral BGE-102, Anti-VEGF, ShamA Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular EdemaDiabetic Macular Edema (DME)Phase 2RecruitingNCT07812090
Nov 2027BioInvent International ABBI1206A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsSolid Tumor, AdultPhase 1/2RecruitingNCT04219254
Nov 2027BioNTechBNT3212, PumitamigA First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Adva…Advanced Solid TumorPhase 1/2RecruitingNCT07147348
Nov 2027Calico Life Sciences LLCFosigotifatorAn Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter DiseaseVanishing White Matter DiseasePhase 1/2RecruitingNCT05757141
Nov 2027Cartesian TherapeuticsDescartes-08Descartes-08 in Autoantibody MyositisAntisynthetase SyndromePhase 2RecruitingNCT07391605
Nov 2027Sino Biopharmaceutical LimitedTQ05105 tabletsA Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host DiseaseChronic Graft Versus Host DiseasePhase 2RecruitingNCT06300320
Nov 2027Sino Biopharmaceutical LimitedTQH3906 capsuleA Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus ErythematosusSystemic Lupus ErythematosusPhase 2RecruitingNCT07509892
Nov 2027Sino Biopharmaceutical LimitedBenmelstobart injection combined with Anlotinib hydrochlor…Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveo…Alveolar Soft Part SarcomaPhase 2RecruitingNCT07548177
Nov 2027Curis IncEmavusertib, ZanubrutinibA Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Oth…Chronic Lymphocytic Leukemia, B-cell MalignanciesPhase 2RecruitingNCT07271667
Nov 2027Eddingpharm (Zhuhai) Co., Ltd.EDP167 100mg, EDP167 200mg, EDP167 300mgPhase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed DyslipidemiaMixed DyslipidemiaPhase 2Not yet recruitingNCT07799129
Nov 2027Eli Lilly and CompanyBrenipatideA Study of Brenipatide in Adult Participants With SchizophreniaSchizophreniaPhase 2RecruitingNCT07410507
Nov 2027Eli Lilly and CompanyBrenipatideA Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)Bipolar DisorderPhase 2RecruitingNCT07286175
Nov 2027Faron Pharmaceuticalsbexmarilimab (1mg/kg), azacitidine, bexmarilimab (3mg/kg)Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic SyndromesHigher Risk Myelodysplastic SyndromesPhase 2RecruitingNCT07672769
Nov 2027Genfleet Therapeutics (Shanghai) Inc.GFH276, Cetuximab, Nab paclitaxel and 5 moreA Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harb…Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma and 1 morePhase 1/2RecruitingNCT07678593
Nov 2027Hemab ApSSutacimigA Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII DeficiencyCongenital Factor VII DeficiencyPhase 2RecruitingNCT07347249
Nov 2027InventisBio Co., LtdD-2570 Dose 1, D-2570 Dose 2, D-2570 Dose 3Study of D-2570 in Subjects With Non-Segmental VitiligoVitiligo, Non-Segmental Vitiligo (NSV)Phase 2RecruitingNCT07625891
Nov 2027Jiangsu Hengrui MedicineSHR-4394, Rezvilutamide, HRS-5041 Tablets and 1 moreA Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate CancerProstate CancerPhase 1/2RecruitingNCT07407283
Nov 2027Jiangsu Hengrui MedicineFH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin, FH-006 ; SHR-1316 ; BP102, FH-006; SHR-1316 ; SHR-8068A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung CancerLung CancerPhase 2RecruitingNCT07241767
Nov 2027Jiangsu Hengrui MedicineRSS0343 TabellaStudy of RSS0343 Tablets in Patients With Non-cystic Fibrosis BronchiectasisAdolescent AsthmaPhase 2RecruitingNCT06775340
Nov 2027Laboratoires TheaT10430 lower dose, T10430 middle dose, T10430 higher doseSafety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia ProgressionMyopiaPhase 2RecruitingNCT07522242
Nov 2027MapLight Therapeutics, Inc.ML-004 (IR)/(ER) tabletML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)Autism Spectrum DisorderPhase 2Active not recruitingNCT05889273
Nov 2027Marea TherapeuticsMAR001Study of MAR001 in Adults With Elevated Triglycerides and Remnant CholesterolHypertriglyceridemiaPhase 2RecruitingNCT07028749
Nov 2027NovelMed TherapeuticsNM8074Study of NM8074 in Patients with Dermatomyositis (DM)DermatomyositisPhase 2Not yet recruitingNCT06887738
Nov 2027Orca Biosystems, Inc.Orca-TTrial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Synd…Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and 1 morePhase 2RecruitingNCT07216443
Nov 2027Qilu Pharmaceutical Co., Ltd.QLS32015, Pomalidomide, Dexamethasone and 3 morePhase II Study of QLS32015 Combination Therapy in the Treatment of Multiple MyelomaRelapsed or Refractory Multiple MyelomaPhase 2RecruitingNCT07018050
Nov 2027Relmada Therapeutics, INC.NDV01 intravesical controlled release formulation of gemci…A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBCNon Muscle Invasive Bladder CancerPhase 2RecruitingNCT06663137
Nov 2027SAB Biotherapeutics, Inc.High Dose SAB-142, Low Dose SAB-142SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 DiabetesType 1 DiabetesPhase 2RecruitingNCT07187531
Nov 2027Serum Institute of India Pvt. Ltd.10µg of R21 with 50µg Matrix-M1, 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 s…, RABIVAX-S and 3 morePfs230D1 + R21 in Matrix-M1 in African School Children and AdultsPrevention of Malaria Transmission and Clinical MalariaPhase 2Active not recruitingNCT07147400
Nov 2027Shenyang Sunshine Pharmaceutical Co., LTD.SSGJ-706, SPGL008, ChemotherapySPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung CancerNon Small Cell Lung CancerPhase 2Not yet recruitingNCT07874984
Nov 2027Vera Therapeutics, Inc.AtaciceptAtacicept in Multiple Glomerular DiseasespMN, IgAN and 3 morePhase 2RecruitingNCT06983028
Nov 2027Argenx SEEfgartigimod PH20 SC - prefilled syringeA Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Anti…Antibody-mediated RejectionPhase 2Active not recruitingNCT06503731
Nov 1, 2027Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.HDM2017, FruquintinibA Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal CancerColorectal Cancer MetastaticPhase 1/2Not yet recruitingNCT07621159
Nov 1, 2027Innovent BiologicsPart B -Telitacicept, Part A - IBI355A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's DiseaseSjögren's DiseasePhase 2Not yet recruitingNCT07836660
Nov 1, 2027ServierS241656, PosaconazoleA Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid MalignanciesAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia and 1 morePhase 1/2Not yet recruitingNCT07719348
Nov 2, 2027PfizerPF-08634404, Ipilimumab, Axitinib and 1 moreSymbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Ad…Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma and 11 morePhase 1/2RecruitingNCT07227415
Nov 3, 2027Hemay Pharmaceutical PTY. LTD.Hemay5394 group, Control groupTo Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic DermatitisSafety, EfficiencyPhase 2Not yet recruitingNCT07877155
Nov 4, 2027Merck & Co.Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate and 6 moreA Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)Malignant NeoplasmPhase 2RecruitingNCT06979596
Nov 5, 2027AstraZenecaAZD6793A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)Phase 2RecruitingNCT07082738
Nov 5, 2027GSKRis-Rez, G-CSFA Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)SarcomaPhase 1/2RecruitingNCT07602777
Nov 5, 2027Haisco Pharmaceutical Group Co., Ltd.HSK39297 200mgQD, HSK39297 300mgQDStudy to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LNLupus Nephritis (LN)Phase 2RecruitingNCT07363460

Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.